This Could be a Game-Changer for NASH Patients

FILE PHOTO: Bottles of medications line the shelves at a pharmacy in Portsmouth

Shares of small-cap, Akero Therapeutics (AKRO) are up more than 115%, or $14.17.

Volume is up to 34.18 million, as compared to daily average volume of 406,516, as well.

All after the company posted positive phase 2b trial data for its experimental nonalcoholic steatohepatitis (NASH) candidate known as efruxifermin (EFX).

“The statistically significant histological improvements observed in the HARMONY study are among the strongest efficacy results reported in NASH to date and, together with strong results in secondary endpoints, show that EFX has the potential to treat the core facets of NASH,” said Stephen Harrison, M.D., medical director of Pinnacle Clinical Research and the HARMONY study’s principal investigator.

“I believe the magnitude and general consistency of results observed across the Phase 2a BALANCED and Phase 2b HARMONY studies increase the probability of success in Phase 3 and position EFX to potentially be a foundational monotherapy for patients with NASH.”

This could be substantial for millions.

At the moment, 12% of adults just in the U.S. deal with this severe liver issue.  And unfortunately, there are no approved drugs or therapies approved by the US FDA to help.

However, should Akero Therapeutics produce even better data, that could all change.